Thursday, August 25, 2022 2:11:06 PM
This is the AIM I see...
AIM
Bid: 0.70 Ask: 0.7089 Last: 0.7001 Chg ($): -0.0025 Vol: 20.03K
https://finviz.com/quote.ashx?t=AIM
AIM
Bid: 0.70 Ask: 0.7089 Last: 0.7001 Chg ($): -0.0025 Vol: 20.03K
https://finviz.com/quote.ashx?t=AIM
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent AIM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:45:38 PM
- AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer • GlobeNewswire Inc. • 05/14/2026 12:41:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 08:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:27:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:50:03 PM
- AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds • GlobeNewswire Inc. • 05/08/2026 12:40:00 PM
- AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential • GlobeNewswire Inc. • 05/07/2026 12:23:00 PM
- AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP • GlobeNewswire Inc. • 04/16/2026 01:00:00 PM
- AIM ImmunoTech Provides Routine Update on Annual Filings • GlobeNewswire Inc. • 04/13/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:33:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/10/2026 08:30:41 PM
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event • GlobeNewswire Inc. • 04/09/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 09:30:45 PM
- AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors • GlobeNewswire Inc. • 03/18/2026 12:36:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:12 PM
- AIM ImmunoTech Announces Closing of its Rights Offering • GlobeNewswire Inc. • 03/07/2026 12:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 10:15:32 PM
- AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million • GlobeNewswire Inc. • 03/04/2026 02:00:00 PM
- AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 03/02/2026 02:00:00 PM
- AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering • GlobeNewswire Inc. • 02/27/2026 02:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/27/2026 01:30:11 PM
- AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 • GlobeNewswire Inc. • 02/25/2026 02:00:00 PM
- AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 02/23/2026 01:55:00 PM
